Pancreatic Cancer Research

ResearcherAmsterdam University Medical CentersActive in the last 2 years

Brigitte C.M. Haberkorn

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0006-6869-7264; OpenAlex author ID A5031689970, A5121185784. Sources: OpenAlex.

Their work

Papers
17
Trials
0
Grants
0
Labs led
0
Collaborators
62
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: 2 papers · 2025: 3 papers · 2026: 5 papers

Papers 17

  1. The value of FOLFIRINOX in advanced pancreatic cancer: balancing efficacy, toxicity, and quality of life. Co-author DOI 10.1007/s00520-026-10568-3↗
  2. Survival of patients with colorectal or pancreatic cancer who received UGT1A1 genotype-guided dosing of irinotecan in the Netherlands (2017-2024): a retrospect… Co-author DOI 10.1016/j.lanepe.2026.101629↗
  3. Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study. Co-author DOI 10.1093/bjs/znag075↗
  4. Real-world implementation of a decision aid for treatment decisions in metastatic pancreatic cancer: a prospective multicenter study across expert centers. Co-author DOI 10.1093/oncolo/oyag373↗
  5. Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial. Co-author DOI 10.1200/jco-25-01935↗
  6. Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multice… Co-author DOI 10.1016/s1470-2045(25)00363-8↗
  7. Delayed gastric emptying after pancreatic cancer surgery impacts time to start of adjuvant treatment but not overall survival: a post-hoc analysis of the PREOP… Co-author DOI 10.1093/bjs/znaf261↗
  8. Patient preferences for pancreatic cancer treatment (PERSEUS): a multicenter discrete choice experiment. Co-author DOI 10.1186/s12955-025-02440-5↗
  9. Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2023.7872↗
  10. Real Life Data and Outcome of FOLFIRINOX Use in Metastatic Pancreatic Cancer Patients in General Hospitals in the Netherlands. Co-author DOI 10.1007/s12029-023-01006-2↗
  11. Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial. Co-author DOI 10.1186/s12885-023-11141-5↗
  12. Treatment Response and Conditional Survival in Advanced Pancreatic Cancer Patients Treated with FOLFIRINOX: A Multicenter Cohort Study. Co-author DOI 10.1155/2022/8549487↗
  13. Serum cytokine levels are associated with tumor progression during FOLFIRINOX chemotherapy and overall survival in pancreatic cancer patients. Co-author DOI 10.3389/fimmu.2022.898498↗
  14. Circulating TP53 mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX. Co-author DOI 10.1177/17588359211033704↗
  15. Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicente… Co-author DOI 10.3390/ijms222010902↗
  16. Impact of nationwide enhanced implementation of best practices in pancreatic cancer care (PACAP-1): a multicenter stepped-wedge cluster randomized controlled t… Co-author DOI 10.1186/s13063-020-4180-z↗
  17. Efficacy and feasibility of stereotactic radiotherapy after folfirinox in patients with locally advanced pancreatic cancer (LAPC-1 trial). Co-author DOI 10.1016/j.eclinm.2019.10.013↗

Closest collaborators

The 25 strongest of 62 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Johanna W. Wilmink · 9 shared papers, 2021–2026 · strength 1.44
  2. Marjolein Y.V. Homs · 9 shared papers, 2021–2026 · strength 1.44
  3. Casper H.J. van Eijck · 9 shared papers, 2019–2026 · strength 1.32
  4. Marc G. Besselink · 8 shared papers, 2021–2026 · strength 1.15
  5. Bas Groot Koerkamp · 8 shared papers, 2019–2026 · strength 1.03
  6. Judith de Vos‐Geelen · 5 shared papers, 2023–2026 · strength 0.94
  7. Bert A. Bonsing · 6 shared papers, 2019–2025 · strength 0.77
  8. Ignace H. J. T. de Hingh · 4 shared papers, 2023–2026 · strength 0.65
  9. Izaak Quintus Molenaar · 3 shared papers, 2023–2026 · strength 0.50
  10. Fleur van der Sijde · 4 shared papers, 2021–2022 · strength 0.50
  11. Hjalmar C. van Santvoort · 3 shared papers, 2023–2026 · strength 0.45
  12. Jacob L. van Dam · 3 shared papers, 2022–2025 · strength 0.43
  13. Quisette P. Janssen · 3 shared papers, 2021–2025 · strength 0.39
  14. Hanneke W.M. van Laarhoven · 2 shared papers, 2025–2026 · strength 0.38
  15. Maarten F. Bijlsma · 2 shared papers, 2025–2026 · strength 0.38
  16. Eveline E. Vietsch · 3 shared papers, 2021–2022 · strength 0.34
  17. Dana A. M. Mustafa · 3 shared papers, 2021–2022 · strength 0.34
  18. Geert Kazemier M · 2 shared papers, 2025–2026 · strength 0.33
  19. Lodewijk A.A. Brosens · 2 shared papers, 2023–2026 · strength 0.30
  20. Casper W.F. van Eijck · 1 shared paper, 2026 · strength 0.29
  21. Anne Margarethe Stiggelbout · 1 shared paper, 2026 · strength 0.29
  22. Aniek E. van Diepen · 1 shared paper, 2026 · strength 0.29
  23. Gaby J. Strijk · 1 shared paper, 2026 · strength 0.29
  24. J. Verstijnen · 1 shared paper, 2024 · strength 0.28
  25. Geertjan van Tienhoven · 2 shared papers, 2023–2025 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.